Johns Hopkins University NCTN Lead Academic Site Program

项目摘要 约翰霍普金斯大学是合作团体的学术成员机构 这项国家肿瘤学研究于1955年成立。几十年来，我们的教职员工 提供强大的临床和实验室科学领导以及管理领导 合作小组。我们的首要目标是提供科学的领导，从而带来创新 翻译科学在约翰霍普金斯大学的临床前和早期试验中通过 机制，如ETCTN到国家临床试验网络(NCTN)，以进一步 发展。我们的教职员工担任研究PI和实验室PI、疾病的领导角色 以及医疗模式委员会主席。我们大部分的贡献和我们最长的联系 仍然属于ECOG-ACRIN，其次是NRG。我们拨款的具体目标是：1) 在NCTN小组及其以疾病为导向的委员会内提供科学领导。2) 带来相关的翻译研究，新的成像和辐射技术，细胞生物学 和分子生物学，进入癌症所有阶段的临床试验。(三)加强和提高 在一个管理机构下建立的协调、协作和包容的基础设施 计划，以支持NCTN项目并促进参与NCI支持的订单 项目，如ETCTN。4)应对支持参与和 在约翰·霍普金斯大学的所有学科、模式、罕见和多样化的患者群体中的应计费用 坎摩尔癌症中心的位置。5)促进初级教员参与我们的所有目标 表彰他们的进步和对NCI癌症计划的贡献。这些目标将是 通过约翰霍普金斯坎摩尔癌症中心的使命完成。《中心》 通过计划项目、RO1和孢子在翻译研究方面取得了卓越的成就 资助金。此外，新药的早期临床试验是在NCI第一阶段进行的。 合同(自1982年以来)。此外，ETCTN赠款还允许开发早期试验， 纳入新的活性生物标记物，以推动该领域的新治疗。约书亚 霍普金斯大学的研究人员专注于通过以下方式加强少数族裔在临床试验中的参与 拨款以及增加整个Johns Hopkins Kimmel的总体临床试验收益 癌症中心网站。

Project Summary Johns Hopkins has been an academic member institution of cooperative groups since the founding of this national oncology research in 1955. Over the decades, our faculty have provided strong clinical and laboratory scientific leadership, and administrative leadership to the cooperative groups. Our primary goal is to provide scientific leadership thus bringing innovative translational science developed in pre-clinical and early phase trials at Johns Hopkins via mechanisms such as the ETCTN to the National Clinical Trials Network (NCTN) for further development. Our faculty serve in leadership roles as study PIs and laboratory PIs, disease and modality committee chairs. The majority of our contributions and our longest association remains with ECOG-ACRIN and secondly with NRG. The specific aims for our grant are 1) To provide scientific leadership within the NCTN groups and their disease-oriented committees. 2) To bring correlative translational research, novel imaging and radiation techniques, cell biology and molecular biology, into clinical trials for all stages of cancer. 3) To strengthen and enhance the coordinated, collaborative, and inclusive infrastructure established under one administrative program in order to support NCTN projects and promote participation in order NCI-supported projects, such as the ETCTN. 4) To address the challenges of supporting participation and accrual across disciplines, modalities, rare and diverse patient populations at all Johns Hopkins Kimmel Cancer Center locations. 5) To promote the involvement of junior faculty in all our aims for their advancement and contribution to the NCI cancer program. These goals will be accomplished through the mission of the Johns Hopkins Kimmel Cancer Center. The Center has achieved excellence in translational research through program project, RO1, and SPORE grants. In addition, early clinical trials of new drugs are conducted under the NCI phase I contract (since 1982). Also the ETCTN grant allows the development of early phase trials that incorporate novel biomarkers of activity in order to advance new treatments in the field. Johns Hopkins investigators have focused on enhancing minority participation in clinical trials through grants as well as increasing overall clinical trial accrual throughout Johns Hopkins Kimmel Cancer Center sites.